Delcath Systems, Inc. (DCTH)
| Market Cap | 673.84M +113.6% |
| Revenue (ttm) | 109.96M +38.1% |
| Net Income | 6.65M +455.4% |
| EPS | 0.16 +390.9% |
| Shares Out | 34.79M |
| PE Ratio | 120.83 |
| Forward PE | 171.82 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 532,479 |
| Open | 19.90 |
| Previous Close | 19.87 |
| Day's Range | 19.33 - 20.01 |
| 52-Week Range | 8.12 - 22.51 |
| Beta | 0.60 |
| Analysts | Strong Buy |
| Price Target | 28.60 (+47.65%) |
| Earnings Date | Nov 9, 2026 |
About DCTH
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for DCTH stock is "Strong Buy." The 12-month stock price target is $28.6, which is an increase of 47.65% from the latest price.
News
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of t...
Delcath Systems to Be Featured on “Health Uncensored with Dr. Drew” in Segment Highlighting Advances in Liver-Directed Cancer Treatment
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that the C...
Delcath Systems management to meet with BTIG
Medical Technology & Digital Health Analyst Thibault holds a meeting with management in New York on November 18 hosted by BTIG.
Delcath Systems Slides: Investor presentation
Delcath Systems has posted slides in relation to its latest quarterly earnings report, which was published on November 11, 2026.
Delcath Systems price target raised to $36 from $32 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Delcath Systems (DCTH) to $36 from $32 and keeps a Buy rating on the shares following the Q3 report. The firm says…
Delcath Systems price target raised to $27 from $21 at Canaccord
Canaccord raised the firm’s price target on Delcath Systems (DCTH) to $27 from $21 and keeps a Buy rating on the shares. The firm said Delcath delivered a record quarter,…
Delcath Systems price target raised to $27 from $24 at Craig-Hallum
Craig-Hallum analyst Chase Knickerbocker raised the firm’s price target on Delcath Systems (DCTH) to $27 from $24 and keeps a Buy rating on the shares. The firm notes Delcath reported…
Delcath Systems Earnings Call Transcript: Q3 2026
Q3 revenue reached a record $35.1M, up 71% YoY, with $7.0M net income and positive operating cash flow. FY revenue guidance rose to $115M–$117M, while treatment-network growth and clinical programs continue.
Delcath Systems Earnings release: Q3 2026
Delcath Systems released its Q3 2026 earnings on November 9, 2026, summarizing the period's financial results.
Delcath Systems Quarterly report: Q3 2026
Delcath Systems has published its Q3 2026 quarterly earnings report on November 9, 2026.
Delcath Systems reports Q3 EPS 17c, consensus (8c)
Reports revenue $35.1M, consensus $25.84M. “We are pleased with the continued momentum in our business, with meaningful progress across both commercial operations and clinical development,” said Gerar...
Delcath Systems sees positive adjusted EBITDA in FY26
The Company’s financial outlook for fiscal year 2026: Total HEPZATO KIT and CHEMOSAT revenue to range from $115 million to $117 million, reflecting an increase in HEPZATO KIT volume of…
Delcath Systems Reports Third Quarter 2026 Results and Business Highlights
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial ...
Delcath Systems to Participate in Upcoming Investor Conferences
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced tha...
Delcath Systems to Host Third Quarter 2026 Earnings Call
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it ...
Delcath Systems highlights clinical program presentations at ESMO Congress 2026
Delcath Systems (DCTH) “announced presentations related to its clinical development programs at the European Society for Medical Oncology Congress 2026, taking place October 23-27 in Madrid, Spain. Th...
Delcath Systems Highlights Clinical Program Presentations at ESMO Congress 2026 and Independent Data on Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal Melanoma
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced pre...
Delcath Systems price target raised to $32 from $30 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Delcath Systems (DCTH) to $32 from $30 and keeps a Buy rating on the shares. The company raised its 2026 revenue guidance…
Delcath Systems Earnings Call Transcript: Q2 2026
Q2 revenue grew 21% year-over-year to $29.1M, driven by strong HEPZATO KIT sales and new center activations. Gross margin reached 90%, and full-year revenue guidance was raised to $104M-$108M, reflecting robust H1 performance and improved operational execution.
Delcath Systems Earnings release: Q2 2026
Delcath Systems released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Delcath Systems Quarterly report: Q2 2026
Delcath Systems has published its Q2 2026 quarterly earnings report on August 6, 2026.
Delcath Systems reports Q2 EPS 7c, consensus (9c)
Reports revenue $29.1M, consensus $26.26M. “Our strong second quarter, including total revenue of $29.1 million and quarterly operating cash flow of $5.7 million, reflects continued momentum in HEPZAT...
Delcath Systems sees positive adjusted EBITDA in FY26
The Company’s financial outlook for fiscal year 2026: Total HEPZATO KIT and CHEMOSAT revenue to range from $104 million to $108 million, reflecting an increase in HEPZATO KIT volume of…
Delcath Systems Reports Second Quarter 2026 Results and Business Highlights
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial ...
Delcath Systems to Participate at the Canaccord Genuity 46th Annual Growth Conference
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced tha...